text stringlengths 1 5.46k |
|---|
About Parvus Parvus is a preclinical-stage private company developing the proprietary novel Navacim™ platform technology with the potential to halt and cure autoimmune disease. Navacims present multivalent peptide-MHCs to T cells which triggers the endogenous expansion and differentiation of the T cells into antigen-sp... |
CONFIDENTIAL 126 |
Schedule 11.2 Disclosures to Additional Representations and Warranties of Parvus |
11.2.8 1) The Novartis License, as terminated by the letter dated June 29, 2020 providing notice of termination thereof. 2) The Genentech License, as terminated by the letter dated March 19, 2021 providing notice of termination thereof. |
11.2.13 1) License to the United States Government, Application Title: Compositions and Methods for the Prevention and Treatment of Autoimmunity, Inventor(s): Moore, Anna V., et al., U.S. Patent Application Number: 12/044,435, Filing Date: 3/7/2008. This invention is a Subject Invention under 35 U.S.C. 200, et seq., an... |
CONFIDENTIAL 127 |
Schedule 14.7.3 ADR Procedures |
Any Dispute referred to ADR under this Agreement shall be resolved as follows: |
1. To begin an ADR proceeding, a Party shall provide written notice to the other Party of the Dispute to be resolved by ADR. Within fourteen (14) days after its receipt of such notice, the other Party may, by written notice to the Party initiating the arbitration, add additional issues to be resolved within the same AD... |
2. Within twenty-one (21) days following the initiation of the ADR proceeding, the Parties shall select a mutually acceptable independent, impartial and conflicts-free neutral to preside in the resolution of all issues in this ADR proceeding. If the Parties are unable to agree on a mutually acceptable neutral within su... |
3. No earlier than twenty-eight (28) days or later than fifty-six (56) days after selection, the Neutral shall hold a hearing to resolve each of the issues identified by the Parties. The ADR proceeding shall take place at a location agreed upon by the Parties. If the Parties cannot agree, the Neutral shall designate a ... |
4. At least seven (7) days prior to the hearing, each Party shall submit the following to the other Party and the Neutral: (a) a copy of all exhibits on which such Party intends to rely in any oral or written presentation to the Neutral; (b) a list of any witnesses such Party intends to call at the hearing, and a short... |
5. The hearing shall be conducted on two (2) consecutive days and shall be governed by the following rules: (a) Each Party shall be entitled to five (5) hours of hearing time to present its case. The Neutral shall determine whether each Party has had the five (5) hours to which it is entitled. (b) Each Party shall be e... |
6. Within seven (7) days following completion of the hearing, each Party may submit to the other Party and the Neutral a post-hearing brief in support of its proposed rulings and remedies; provided that such brief shall not contain or discuss any new evidence and shall not exceed ten (10) pages. This page limitation sh... |
7. The Neutral shall rule on each disputed issue within fourteen (14) days following completion of the hearing. Such ruling shall adopt in its entirety the proposed ruling and remedy of one (1) of the Parties on each disputed issue but may adopt one (1) Party's proposed rulings and remedies on some issues and the other... |
8. The Neutral shall be paid a reasonable fee plus expenses. These fees and expenses, along with the reasonable legal fees and expenses of the prevailing Party (including all expert witness fees and expenses), the fees and expenses of a court reporter, and any expenses for a hearing room, shall be paid as follows: (a) ... |
9. The rulings of the Neutral and the allocation of fees and expenses shall be binding, non-reviewable, and non-appealable, and may be entered as a final judgment in any court having jurisdiction. |
10. Except as provided in paragraph 9 or as required by law, the existence of the Dispute, any settlement negotiations, the ADR proceeding, any submissions (including exhibits, testimony, proposed rulings, and briefs), and the rulings shall be deemed to be Confidential Information of both Parties. The Neutral shall hav... |
11. All ADR proceedings shall be conducted in the English language. |
12. Each Party shall have the right to be represented by counsel in all aspects of any ADR proceeding. |
EXECUTION VERSION CONFIDENTIAL |
COLLABORATION AND OPTION AGREEMENT |
By and between |
ABCELLERA BIOLOGICS INC. |
AND |
ABBVIE GLOBAL ENTERPRISES LTD. |
TABLE OF CONTENTS |
ARTICLE 1 DEFINITIONS ....................................................................................................1 |
ARTICLE 2 DEVELOPMENT; ACQUISITION OPTION ..................................................21 |
2.1 Overview. ...............................................................................................................21 |
2.2 Target Programs. ....................................................................................................21 |
2.3 Research Target Substitution. ................................................................................21 |
2.4 Research Plans. ......................................................................................................22 |
2.5 Conduct of Research Activities. ............................................................................23 |
2.6 IP Assignment Obligation. .....................................................................................24 |
2.7 Acquisition Option. ................................................................................................25 |
2.8 Activities under Research Plan after Acquisition Option Effective Date.. ............25 |
2.9 HSR. .......................................................................................................................26 |
2.10 No Exercise of Acquisition Option. .......................................................................26 |
ARTICLE 3 MANAGEMENT OF THE RESEARCH .........................................................26 |
3.1 Program Leader. .....................................................................................................26 |
3.2 Joint Governance Committee. ................................................................................26 |
3.3 Responsibilities. .....................................................................................................27 |
3.4 Meetings and Minutes. ...........................................................................................27 |
3.5 Procedural Rules. ...................................................................................................28 |
3.6 Decision-Making. ...................................................................................................28 |
3.7 Alliance Managers. ................................................................................................29 |
3.8 Discontinuation of the JGC. ...................................................................................29 |
3.9 Interactions Between the JGC and Internal Teams. ...............................................29 |
3.10 Working Groups.....................................................................................................29 |
3.11 Expenses. ...............................................................................................................30 |
3.12 Authority. ...............................................................................................................30 |
ARTICLE 4 ASSIGNMENT OF ACQUIRED ASSETS ......................................................30 |
4.1 Assignment and License Grants to AbbVie. ..........................................................30 |
4.2 License Grants to AbCellera. .................................................................................31 |
4.3 Sublicensing Rights. ..............................................................................................31 |
4.4 No Other Rights. ....................................................................................................32 |
ARTICLE 5 ABBVIE ACTIVITIES .....................................................................................32 |
5.1 AbCellera Transition Obligation. ...........................................................................32 |
5.2 AbbVie Development and Commercialization.. ....................................................32 |
5.3 Alloy Selection Notice; Updated Alloy Selection Notice. .....................................32 |
ARTICLE 6 GENERAL PROVISIONS RELATING TO ACTIVITIES .............................33 |
6.1 Compliance. ...........................................................................................................33 |
6.2 Subcontracting. ......................................................................................................33 |
6.3 Records and Audits. ...............................................................................................34 |
ARTICLE 7 UPFRONT FEE; MILESTONES AND EARN-OUTS; PAYMENTS ............34 |
7.1 Upfront Fee. ...........................................................................................................34 |
7.2 Additional Option Program Fee. ............................................................................35 |
7.3 Substitution Fee. ....................................................................................................35 |
7.4 Acquisition Option Exercise Fee. ..........................................................................35 |
7.5 Development and Regulatory Milestone Payments. ..............................................35 |
7.7 Sales-Based Milestone Payments. .........................................................................37 |
7.8 Earn-Out. ................................................................................................................38 |
7.9 Earn-Out Term.. ....................................................................................................39 |
7.10 Third-Party Licenses. .............................................................................................39 |
7.11 Estimated Sales Levels. .........................................................................................40 |
7.12 Reports; Payment of Earn-Out. ..............................................................................40 |
7.13 Reports; Quarterly Net Sales Estimate. .................................................................40 |
7.14 Financial Records. ..................................................................................................40 |
7.15 Audit; Audit Dispute. .............................................................................................41 |
7.16 Methods of Payments; Offsets. ..............................................................................41 |
7.17 Taxes. .....................................................................................................................42 |
7.18 Late Payments. .......................................................................................................42 |
7.19 Financial Obligations under In-License Agreements. ...........................................43 |
ARTICLE 8 EXCLUSIVITY; CHANGE OF CONTROL ...................................................43 |
8.1 Exclusivity. ............................................................................................................43 |
ARTICLE 9 INTELLECTUAL PROPERTY RIGHTS ........................................................44 |
9.1 Ownership of Intellectual Property; Disclosure. ....................................................44 |
9.2 Restriction on AbCellera Prosecution of Research Patents. ..................................45 |
9.3 Cooperation. ...........................................................................................................45 |
9.4 Infringement Claims by Third Parties. ...................................................................45 |
9.5 Third Party Licenses. .............................................................................................46 |
9.6 Product Trademarks. ..............................................................................................46 |
9.7 Inventor's Remuneration. ......................................................................................46 |
9.8 International Nonproprietary Name. ......................................................................46 |
ARTICLE 10 CONFIDENTIALITY .......................................................................................46 |
10.1 Product Information. ..............................................................................................46 |
10.2 Confidentiality Obligations. ...................................................................................47 |
10.3 Permitted Disclosures. ...........................................................................................48 |
10.4 Use of Name. .........................................................................................................49 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.